Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 9: Line 9:
!
!
!
!
! rowspan="5" |Age range
!
!
! colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
!
!
! colspan="10" |Clinical manifestations
! colspan="10" rowspan="2" |Para−clinical findings
! colspan="10" rowspan="2" |Para−clinical findings
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
Line 21: Line 20:
!
!
!
!
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
!
! rowspan="4" |Age range
! rowspan="4" |History
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
|
|
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
!
|-
|-
!
!
Line 30: Line 33:
!
!
!
!
|
|
! colspan="9" |Lab Findings
! colspan="9" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
|-
|-
!
!
!
!
!
Line 39: Line 45:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!
! rowspan="2" |
! rowspan="2" |
! rowspan="2" |
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
!
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! rowspan="2" |Other
! colspan="3" |CBC
! colspan="3" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
Line 55: Line 59:
!
!
|-
|-
!Myelosuppression
!Decreased platelet production
!Platelet destruction in bloodstream
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!Platelet destruction in spleen/liver
!History
!Inherited
!
!Acquried
!BP
!Plt
!Plt
!HB
!HB
Line 66: Line 71:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
|-
|-
! rowspan="14" |Hematology
! rowspan="15" |Hematology
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
!Myelodysplastic syndromes
!Myelodysplastic syndromes
!
!
| +
| +
|
|
|
|
|
|
Line 81: Line 88:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 103: Line 108:
!
!
| +
| +
|
|
|
|
|
|
Line 111: Line 118:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 133: Line 138:
!
!
| +
| +
|
|
|
|
|
|
Line 141: Line 148:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 163: Line 168:
!
!
| +
| +
|
|
|
|
|
|
Line 171: Line 178:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 225: Line 230:
!
!
!+
!+
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!DIC
!
!
!
!
!
!
!
Line 253: Line 289:
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
|
|
|
|
|
|
Line 263: Line 301:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 283: Line 319:
|-
|-
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
|
|
|
|
|
|
Line 293: Line 331:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
|
Line 313: Line 349:
|-
|-
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
|
|
|
|
|
|
Line 323: Line 361:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
|
Line 343: Line 379:
|-
|-
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
|
|
|
|
|
|
Line 353: Line 391:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 373: Line 409:
|-
|-
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
|
|
|
|
|
|
Line 383: Line 421:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
|
Line 403: Line 439:
|-
|-
! align="center" style="background:#DCDCDC;" + |Alport syndrome
! align="center" style="background:#DCDCDC;" + |Alport syndrome
|
|
|
|
|
|
Line 413: Line 451:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|
|
|
|
Line 433: Line 469:
|-
|-
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
|
|
|
|
|
|
Line 443: Line 481:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 497: Line 533:
!
!
|Antibody-mediated platelet destruction
|Antibody-mediated platelet destruction
|
| +
|
|
|
|
Line 506: Line 544:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 528: Line 564:
!
!
!
!
|
|
|
|
|
|
Line 537: Line 575:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 622: Line 658:
! align="center" style="background:#DCDCDC;" + |Sepsis
! align="center" style="background:#DCDCDC;" + |Sepsis
!Direct bone marrow suppression
!Direct bone marrow suppression
!+
!+
!+
!
!
!
!
!
Line 631: Line 669:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 652: Line 688:
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
!Immune thrombocytopenia
!Immune thrombocytopenia
!
!+
!
!
!
!
Line 661: Line 699:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 682: Line 718:
! align="center" style="background:#DCDCDC;" + |Tick-borne infection
! align="center" style="background:#DCDCDC;" + |Tick-borne infection
|
|
|
| +
|
|
|
|
Line 691: Line 729:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 746: Line 782:
!Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
!Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
!
!
!
!+
!
!
!
!
Line 776: Line 812:
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! align="center" style="background:#DCDCDC;" + |Malaria
! align="center" style="background:#DCDCDC;" + |Malaria
|
|
|
|
|
|
Line 786: Line 824:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 806: Line 842:
|-
|-
! align="center" style="background:#DCDCDC;" + |Babesiosis  
! align="center" style="background:#DCDCDC;" + |Babesiosis  
|
|
|
|
|
|
Line 816: Line 854:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 849: Line 885:
* Quinine
* Quinine
|Occurrence of drug-dependent, platelet-reactive antibodies
|Occurrence of drug-dependent, platelet-reactive antibodies
|
| +
|
|
|
|
Line 858: Line 896:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 880: Line 916:
!
!
|
|
|
| +
|
|
|
|
Line 889: Line 927:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 912: Line 948:
|
|
| +
| +
|
|
|
|
|
|
Line 920: Line 958:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 943: Line 979:
|Predictable, dose-dependent myelosuppression
|Predictable, dose-dependent myelosuppression
| +
| +
|
|
|
|
|
|
Line 951: Line 989:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 972: Line 1,008:
!OTC agents
!OTC agents
!Quinine-containing beverages
!Quinine-containing beverages
|
|
|
|
|
|
Line 982: Line 1,020:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,006: Line 1,042:
|
|
| +
| +
|
|
|
|
|
|
Line 1,014: Line 1,052:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,035: Line 1,071:
!Portal hypertension
!Portal hypertension
!
!
|
|
|
|
|
|
Line 1,045: Line 1,083:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,069: Line 1,105:
!platelet destruction  
!platelet destruction  
!
!
!
!+
!
!
!
!
Line 1,100: Line 1,136:
!platelet destruction  
!platelet destruction  
!
!
!
!+
!
!
!
!
Line 1,131: Line 1,167:
!platelet destruction  
!platelet destruction  
!
!
!
!+
!
!
!
!
Line 1,162: Line 1,198:
!
!
!
!
!
!+
!
!
!
!
Line 1,225: Line 1,261:
!
!
!
!
!
!+
!
!
!
!

Revision as of 21:31, 14 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Mechanism Clinical manifestations Para−clinical findings Gold standard Associated findings
Age range History Symptoms Signs
Lab Findings Imaging
Severity Fever Rash Bleeding Splenomegaly Jaundice Other CBC PBS Bone marrow exam
Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried BP Plt HB WBC PT PTT BT UA
Hematology Bone marrow disorders Myelodysplastic syndromes +
Aplastic anemia +
Acute leukemia +
Paroxysmal nocturnal hemoglobinuria (PNH) + Diagnosis of exclusion
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP) +
Hemolytic uremic syndrome (HUS) +
DIC
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Nutrient deficiencies Folate, vitamin B12, copper an autoimmune mechanism +
Rheumatologic/autoimmune disorders Immune thrombocytopenia Antibody-mediated platelet destruction + Moderate to severe -
Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
Infection-induced Bacterial infections Sepsis Direct bone marrow suppression + +
Helicobacter pylori Immune thrombocytopenia +
Tick-borne infection +
Viral infections HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
+
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus +
Intracellular parasites Malaria
Babesiosis
Medication/toxicity Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies +
Heparin-induced thrombocytopenia +
Cytotoxic chemotherapy +
Radiation therapy Predictable, dose-dependent myelosuppression +
OTC agents Quinine-containing beverages
GI Chronic liver disease + Mild
Portal hypertension
Vascular Giant capillary hemangioma platelet destruction +
Aortic aneurysm platelet destruction +
Cardiopulmonary bypass platelet destruction +
Other Alcohol +
Post-transfusion purpura immune-mediated platelet destruction
Gestational thrombocytopenia +